浅谈急性高原病的发生发展机制及预防和治疗的最新研究进展
The Latest Research Progress on the Occurrence and Development Mechanism, Prevention and Treatment of Acute Mountain Sickness
DOI: 10.12677/ACM.2023.132371, PDF,   
作者: 阿力米热·叶尔江, 张向阳*, 迪丽努尔·买买提依明*：新疆医科大学第一附属医院综合心脏内科，新疆 乌鲁木齐；伊利亚尔·尼加提：新疆医科大学中心实验室，新疆 乌鲁木齐
关键词: 急性高原病；心血管病；发生发展机制；预防；治疗；Acute Mountain Sickness； Cardiovascular Disease； Mechanism of Occurrence and Development； Prevention； Treatment
摘要: 上升至海拔高于2500米以上的高原地区可能会发生高原反应。高原环境中空气稀薄，大气压和氧分压低，紫外线照射强，早晚温差大、天气恶劣。随着海拔的升高，空气越来越稀薄，导致空气中氧含量亦逐渐减少，当出现高原反应时如不及时干预可能会引起高原肺水肿，甚至高原脑水肿，严重时威胁生命。近年来，随着我国旅游业、经济的日渐发展，我们与高海拔地区的接触也越来越多，并认识到高原病的研究格为重要，因此使研究高原病的发生发展机制及预防和治疗的热潮成为研究热点。本文章中讨论急性高原病(AMS)相关心血管疾病相关的发生发展机制及预防和治疗的防治基本趋势，旨在能够快速地了解到高原病的相关信息及研究状况，同时也为高原病的进一步研究提供理论参考。
Abstract: Altitude sickness can occur in high altitude areas above 2500 meters. In the plateau environment, the air is thin, the atmospheric pressure and oxygen partial pressure are low, the ultraviolet radia-tion is strong, the temperature difference between morning and evening is large, and the weather is bad. With the increase of altitude, the air becomes thinner and thinner, resulting in a gradual re-duction of oxygen content in the air. If timely intervention is not provided, altitude sickness may cause altitude pulmonary edema or even altitude brain edema, which may threaten life in serious cases. In recent years, with the increasing development of tourism and economy in China, we have more and more contact with the high altitude area, and realize that the research on plateau disease is important, so it is the hot research topic of the occurrence and development mechanism of plat-eau disease, prevention and treatment. This article discusses the occurrence and development mechanism of acute mountain sickness (AMS) related cardiovascular diseases and the basic trend of prevention and treatment, aiming to quickly understand the relevant information and research status of AMS, and also provide theoretical reference for further research on AMS.
文章引用：阿力米热·叶尔江, 伊利亚尔·尼加提, 张向阳, 迪丽努尔·买买提依明. 浅谈急性高原病的发生发展机制及预防和治疗的最新研究进展[J]. 临床医学进展, 2023, 13(2): 2620-2626. https://doi.org/10.12677/ACM.2023.132371

参考文献

[1] Simancas-Racines, D., Arevalo-Rodriguez, I., Osorio, D., Franco, J.V., Xu, Y. and Hidalgo, R. (2018) Interventions for Treating Acute High Altitude Illness. Cochrane Database of Systematic Reviews, 6, Article ID: CD009567. [Google Scholar] [CrossRef] 
[2] Lee, E., Yim, S., Lee, S.K. and Park, H. (2002) Two Transactivation Domains of Hypoxia-Inducible Factor-1alpha Regulated by the MEK-1/p42/p44 MAPK Pathway. Mole-cules and Cells, 14, 9-15.
[3] Dzhalilova, D. and Makarova, O. (2020) Differences in Tolerance to Hypoxia: Physio-logical, Biochemical, and Molecular-Biological Characteristics. Biomedicines, 8, Article No. 428. [Google Scholar] [CrossRef] [PubMed]
[4] Richalet, J.P., Larmignat, P., Poitrine, E., Letournel, M. and Canouï-Poitrine, F. (2012) Physiological Risk Factors for Severe High-Altitude Illness: A Prospective Cohort Study. American Journal of Respiratory and Critical Care Medicine, 185, 192-198. [Google Scholar] [CrossRef] 
[5] Schneider, M., Bernasch, D., Weymann, J., et al. (2002) Acute Mountain Sickness: Influence of Susceptibility, Preexposure, and Ascent Rate. Medicine and Science in Sports and Exer-cise, 34, 1886-1891. [Google Scholar] [CrossRef] [PubMed]
[6] Webb, J.D., Coleman, M.L. and Pugh, C.W. (2009) Hypoxia, Hypoxia-Inducible Factors (HIF), HIF Hydroxylases and Oxygen Sensing. Cellular and Molecular Life Sci-ences, 66, 3539-3554. [Google Scholar] [CrossRef] [PubMed]
[7] Minamino, T., Christou, H., Hsieh, C.M., Liu, Y., Dhawan, V., Abraham, N.G., Perrella, M.A., Mitsialis, S.A. and Kourembanas, S. (2001) Targeted Expression of Heme Oxygenase-1 Prevents the Pulmonary Inflammatory and Vascular Responses to Hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 98, 8798-803. [Google Scholar] [CrossRef] [PubMed]
[8] Agita, A. and Alsagaff, M.T. (2017) Inflammation, Immunity, and Hypertension. Acta Medica Indonesiana, 49, 158-165.
[9] Maron, B.A., Kovacs, G., Vaidya, A., Bhatt, D.L., Nishi-mura, R.A., Mak, S., Guazzi, M. and Tedford, R.J. (2020) Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure: JACC Review Topic of the Week. Journal of the American College of Cardiology, 76, 2671-2681. [Google Scholar] [CrossRef] [PubMed]
[10] Villafuerte, F.C., Macarlupú, J.L., Anza-Ramírez, C., Cor-rales-Melgar, D., Vizcardo-Galindo, G., Corante, N. and León-Velarde, F. (2014) Decreased Plasma Soluble Erythropoi-etin Receptor in High-Altitude Excessive Erythrocytosis and Chronic Mountain Sickness. Journal of Applied Physiology, 117, 1356-1362. [Google Scholar] [CrossRef] [PubMed]
[11] West, J.B. (2011) Con: Headache Should Not Be a Required Symptom for the Diagnosis of Acute Mountain Sickness. High Altitude Medicine & Biology, 12, 23-25. [Google Scholar] [CrossRef] [PubMed]
[12] Marshall, J.M. (2015) Interactions between Local Dilator and Sympa-thetic Vasoconstrictor Influences in Skeletal Muscle In acute and Chronic Hypoxia. Experimental Physiology, 100, 1400-1411. [Google Scholar] [CrossRef] 
[13] Bärtsch, P. and Bailey, D.M. (2014) Acute Mountain Sickness and High Altitude Cerebral Oedema. In: Swenson, E. and Bärtsch, P., Eds., High Altitude, Springer, New York, 379-404. [Google Scholar] [CrossRef] 
[14] Davis, C. and Hackett, P. (2017) Advances in the Prevention and Treatment of High Altitude Illness. Emergency Medicine Clinics, 35, 241-260. [Google Scholar] [CrossRef] [PubMed]
[15] Sampson, J.B., Cymerman, A., Burse, R.L., Maher, J.T. and Rock, P.B. (1983) Procedures for the Measurement of Acute Mountain Sickness. Aviation, Space, and Environmental Medicine, 54, 1063-1073.
[16] Wilson, M.H., Newman, S. and Imray, C.H. (2009) The Cerebral Effects of Ascent to High Alti-tudes. The Lancet Neurology, 8, 175-191. [Google Scholar] [CrossRef] 
[17] Smedley, T. and Grocott, M.P. (2013) Acute High-Altitude Illness: A Clinically Orientated Review. British Journal of Pain, 7, 85-94. [Google Scholar] [CrossRef] [PubMed]
[18] Hall, D.P., Duncan, K. and Baillie, J.K. (2011) High Altitude Pulmonary Oedema. BMJ Military Health, 157, 68-72. [Google Scholar] [CrossRef] [PubMed]
[19] Maggiorini, M. (2010) Prevention and Treatment of High-Altitude Pulmonary Edema. Progress in Cardiovascular Diseases, 52, 500-506. [Google Scholar] [CrossRef] [PubMed]
[20] Scherrer, U., Rexhaj, E., Jayet, P.Y., Allemann, Y. and Sartori, C. (2010) New Insights in the Pathogenesis of High-Altitude Pulmonary Edema. Progress in Cardiovascular Diseases, 52, 485-492. [Google Scholar] [CrossRef] [PubMed]
[21] Imray, C., Wright, A., Subudhi, A. and Roach, R. (2010) Acute Mountain Sickness: Pathophysiology, Prevention, and Treatment. Progress in Cardiovascular Diseases, 52, 467-484. [Google Scholar] [CrossRef] [PubMed]
[22] Wu, T., Ding, S., Liu, J., et al. (2006) Ataxia: An Early Indicator in High Altitude Cerebral Edema. High Altitude Medicine & Biology, 7, 275-280. [Google Scholar] [CrossRef] [PubMed]
[23] Consolazio, C.F., Matoush, L.O., Johnson, H.L., et al. (1969) Effects of a High-Carbohydrate Diet on Performance and Clinical Symptomology after Rapid Ascent to High Altitude. Federa-tion Proceedings, 28, 937-943.
[24] Golja, P., Flander, P., Klemenc, M., Maver, J. and Princi, T. (2008) Carbohydrate Ingestion Improves Oxygen Delivery in Acute Hypoxia. High Altitude Medicine & Biology, 9, 53-62. [Google Scholar] [CrossRef] [PubMed]
[25] Lawless, N.P., Dillard, T.A., Torrington, K.G., Davis, H.Q. and Ka-mimori, G. (1999) Improvement in Hypoxemia at 4600 Meters of Simulated Altitude with Carbohydrate Ingestion. Avia-tion, Space, and Environmental Medicine, 70, 874-878.
[26] Hackett, P.H. and Roach, R.C. (2001) High-Altitude Illness. New England Journal of Medicine, 345, 107-114. [Google Scholar] [CrossRef] 
[27] Pollard, A.J. (1992) Altitude Induced Illness. British Medi-cal Journal, 304, 1324-1325. [Google Scholar] [CrossRef] [PubMed]
[28] Ellsworth, A.J., Larson, E.B. and Strickland, D. (1987) A Ran-domized Trial of Dexamethasone and Acetazolamide for Acute Mountain Sickness Prophylaxis. The American Journal of Medicine, 83, 1024-1030. [Google Scholar] [CrossRef] [PubMed]
[29] Committee to Advise on Tropical Medicine and Travel (CATMAT) (2007) Statement on High-Altitude Illnesses. An Advisory Committee Statement (ACS). Canada Com-municable Disease Report, 33, 1-20.
[30] Nerín, M.A., Palop, J., Montaño, J.A., Morandeira, J.R. and Vázquez, M. (2006) Acute Mountain Sickness: Influence of Fluid Intake. Wilderness & Environmental Medicine, 17, 215-220. [Google Scholar] [CrossRef] 
[31] Richardson, A., Watt, P. and Maxwell, N. (2009) Hydration and the Physiological Responses to Acute Normobaric Hypoxia. Wilderness & Environmental Medicine, 20, 212-220. [Google Scholar] [CrossRef] 
[32] van Patot, M.C., Leadbetter 3rd., G., Keyes, L.E., et al. (2008) Prophylactic Low-Dose Acetazolamide Reduces the Incidence and Severity of Acute Mountain Sickness. High Altitude Medicine & Biology, 9, 289-293. [Google Scholar] [CrossRef] [PubMed]
[33] Basnyat, B., Gertsch, J.H., Johnson, E.W., et al. (2003) Efficacy of Low-Dose Acetazolamide (125 mg BID) for the Prophylaxis of Acute Mountain Sickness: A Prospective, Double-Blind, Randomized, Placebo-Controlled Trial. High Altitude Medicine & Biology, 4, 45-52. [Google Scholar] [CrossRef] [PubMed]
[34] Dumont, L., Mardirosoff, C. and Tramer, M. (2003) Efficacy and Harm of Pharmacological Prevention of Acute Mountain Sickness: Quantitative Systematic Review. British Medical Journal, 321, 267-272. [Google Scholar] [CrossRef] [PubMed]
[35] Basnyat, B., Gertsch, J.H., Holck, P.S., et al. (2006) Acetazolamide 125 mg BD Is Not Significantly Different from 375 mg BD in the Prevention of Acute Mountain Sickness: The Prophy-lactic Acetazolamide Dosage Comparison for Efficacy (PACE) Trial. High Altitude Medicine & Biology, 7, 17-27. [Google Scholar] [CrossRef] [PubMed]
[36] Carlsten, C., Swenson, E.R. and Ruoss, S. (2004) A Dose-Response Study of Acetazolamide for Acute Mountain Sickness Prophylaxis in Vacationing Tourists at 12,000 Feet (3630 m). High Altitude Medicine & Biology, 5, 33-39. [Google Scholar] [CrossRef] [PubMed]
[37] Greene, M.K., Kerr, A.M., McIntosh, I.B. and Prescott, R.J. (1981) Acetazolamide in Prevention of Acute Mountain Sickness: A Double-Blind Controlled Cross-Over Study. British Medical Journal, 283, 811-813. [Google Scholar] [CrossRef] [PubMed]
[38] Her, Y., Kil, M.S., Park, J.H., Kim, C.W. and Kim, S.S. (2011) Stevens-Johnson Syndrome Induced by Acetazol-Amide. The Journal of Dermatology, 38, 272-275. [Google Scholar] [CrossRef] [PubMed]
[39] Collier, D.J., Wolff, C.B., Hedges, A.-M., et al. (2016) Benzolamide Improves Oxygenation and Reduces Acute Mountain Sickness during a High-Altitude Trek and Has Fewer Side Effects than Acetazolamide at Sea Level. Pharmacology Research & Perspectives, 4, e00203. [Google Scholar] [CrossRef] [PubMed]
[40] Ellsworth, A.J., Meyer, E.F. and Larson, E.B. (1991) Acetazolamide or Dexamethasone Use versus Placebo to Prevent Acute Mountain Sickness on Mount Rainier. Western Journal of Medi-cine, 154, 289-293.
[41] Chen, G.-Z., Zheng, C.-R., Qin, J., et al. (2015) Inhaled Budesonide Prevents Acute Mountain Sickness in Young Chinese Men. Journal of Emergency Medicine, 48, 197-206. [Google Scholar] [CrossRef] [PubMed]
[42] Zheng, C.-R., Chen, G.-Z., Yu, J., et al. (2014) Inhaled Budesonide and Oral Dexamethasone Prevent Acute Mountain Sickness. The American Journal of Medicine, 127, 1001-1009. [Google Scholar] [CrossRef] [PubMed]
[43] Luks, A.M., McIntosh, S.E., Grissom, C.K., Au-erbach, P.S., Rodway, G.W., Schoene, R.B., et al. (2010) Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness. Wilderness & Environmental Medicine, 21, 146-155. [Google Scholar] [CrossRef] [PubMed]
[44] Bartsch, P., Maggiorini, M., Ritter, M., Noti, C., Vock, P. and Oelz, O. (1991) Prevention of High-Altitude Pulmonary Edema by Nifedipine. New England Journal of Medicine, 325, 1284-1289. [Google Scholar] [CrossRef] 
[45] Sartori, C., Allemann, Y., Duplain, H., Lepori, M., Egli, M., Lipp, E., et al. (2002) Salmeterol for the Prevention of High-Altitude Pulmonary Edema. New England Journal of Medi-cine, 346, 1631-1636. [Google Scholar] [CrossRef] 
[46] Maggiorini, M., Brunner-La Rocca, H.P., Peth, S., Fischler, M., Bohm, T., Bernheim, A., et al. (2006) Both Tadalafil and Dexamethasone May Reduce the Incidence of High-Altitude Pulmonary Edema: A Randomized Trial. Annals of Internal Medicine, 145, 497-506. [Google Scholar] [CrossRef] [PubMed]
[47] Luks, A.M., Auerbach, P.S., Freer, L., Grissom, C.K., Keyes, L.E., McIntosh, S.E., Rodway, G.W., Schoene, R.B., Zafren, K. and Hackett, P.H. (2019) Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Acute Altitude Illness: 2019 Update. Wilderness & Environmental Medicine, 30, S3-S18. [Google Scholar] [CrossRef] [PubMed]
[48] Gertsch, J.H., Corbett, B., Holck, P.S., Mulcahy, A., Watts, M., Stillwagon, N.T., et al. (2012) Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): Randomized, Controlled Trial of Ibuprofen versus Placebo for Prevention of Altitude Illness. Wilderness & Environmental Medicine, 23, 307-315. [Google Scholar] [CrossRef] [PubMed]
[49] Lipman, G.S., Kanaan, N.C., Holck, P.S., Constance, B.B. and Gertsch, J.H. (2012) Ibuprofen Prevents Altitude Illness: A Randomized Controlled Trial for Prevention of Altitude Ill-ness with Nonsteroidal Anti-Inflammatories. Annals of Emergency Medicine, 59, 484-490. [Google Scholar] [CrossRef] [PubMed]
[50] Lundeberg, J., Feiner, J.R., Schober, A., Sall, J.W., Eilers, H. and Bickler, P.E. (2018) Increased Cytokines at High Altitude: Lack of Effect of Ibuprofen on Acute Mountain Sick-ness, Physiological Variables, or Cytokine Levels. High Altitude Medicine & Biology, 19, 249-258. [Google Scholar] [CrossRef] [PubMed]

为你推荐